A phase 2A, randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of PF-06700841 i nsubjects with moderate to severe plaque psoriasis.
Qualified Participants Must:
Be between 18 and 75 years of age
Have been diagnosed with psoriasis for at least 6 months
Have at least 10% body surface area of psoriasis
Qualified Participants May Receive:
Study related medication and visits at no cost as well as compensation for their time and travel.